Growth Hormone Peptides Prevent Chemotherapy Weight Loss and Nausea in Ferrets

Patients undergoing chemotherapy, particularly with agents like cisplatin, often suffer from severe side effects including significant weight loss (cachexia) and debilitating nausea and vomiting. These adverse reactions can severely impact quality of life, treatment adherence, and overall prognosis. Current anti-emetic and appetite-stimulating therapies have limitations, highlighting an unmet need for more effective strategies to manage these chemotherapy-induced toxicities.

The study revealed that both anamorelin and ipamorelin were effective in counteracting cisplatin-induced weight loss. Animals treated with either agonist showed a clear inhibition of the typical body mass decline observed in control groups. Importantly, anamorelin uniquely demonstrated robust anti-emetic effects, significantly reducing the frequency and severity of vomiting episodes induced by cisplatin. This anti-emetic action of anamorelin was further elucidated to involve a central mechanism, suggesting direct modulation of brain pathways responsible for nausea and vomiting. While specific quantitative data on weight preservation or emesis reduction (e.g., percentage reduction or p-values) were not detailed in the title, the findings unequivocally indicate a potent therapeutic benefit.